Immunizations could be administered within minutes where and when a disease is breaking out.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
University of Washington engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.
“We’re really excited about this technology because it makes it possible to produce a vaccine on the spot. For instance, a field doctor could see the beginnings of an epidemic, make vaccine doses right away, and blanket vaccinate the entire population in the affected area to prevent the spread of an epidemic,” said François Baneyx, a UW professor of chemical engineering and lead author of a recent paper published online in the journal Nanomedicine.
In typical vaccines, weakened pathogens or proteins found on the surface of microbes and viruses are injected into the body along with compounds called adjuvants to prepare a person’s immune system to fight a particular disease. But standard formulations don’t always work, and the field is seeking ways to manufacture vaccines quicker, cheaper and tailored to specific infectious agents, Baneyx said.
The UW team injected mice with nanoparticles synthesized using an engineered protein that both mimics the effect of an infection and binds to calcium phosphate, the inorganic compound found in teeth and bones. After eight months, mice that contracted the disease made threefold the number of protective “killer” T-cells – a sign of a long-lasting immune response – compared with mice that had received the protein but no calcium phosphate nanoparticles.
The nanoparticles appear to work by ferrying the protein to the lymph nodes where they have a higher chance of meeting dendritic cells, a type of immune cell that is scarce in the skin and muscles, but plays a key role in activating strong immune responses.
In a real-life scenario, genetically engineered proteins based on those displayed at the surface of pathogens would be freeze-dried or dehydrated and mixed with water, calcium and phosphate to make the nanoparticles. This should work with many different diseases and be especially useful for viral infections that are hard to vaccinate against, Baneyx said.
He cautioned, however, that it has only been proven in mice, and the development of vaccines using this method hasn’t begun for humans.
The Latest on: Vaccines
via Google News
The Latest on: Vaccines
- Race is on for a coronavirus cure with 115 vaccines in the works worldwideon April 10, 2020 at 1:00 am
There are now 115 vaccines under development to prevent COVID-19, according to a wide-ranging worldwide review by the journal Nature.
- Pediatric mobile clinic makes house calls for checkups, vaccineson April 9, 2020 at 3:18 pm
"We use the same personal protection equipment that we would have in the office, but the advantage is mom doesn't have to pack up baby, bring the child less than two into the office, potentially get ...
- Coronavirus Testing, Vaccines & Treatments: What You Should Knowon April 9, 2020 at 1:48 pm
In this episode of ETF Spotlight, I speak with biotech expert Brad Loncar, about latest developments in coronavirus testing, vaccines and treatments. The US now has more than 430,000 confirmed cases ...
- Pfizer and BioNTech Aim to Start Testing Coronavirus Vaccines in Humans by Late Aprilon April 9, 2020 at 7:31 am
BioNTech also could receive future milestone payments of up to $563 million. Pfizer is funding all vaccine development costs initially, but BioNTech will repay half of those costs to Pfizer from sales ...
- Polio Vaccines Market Analysis Report 2025 | Business Insights, market conditions, company overviews Business Opportunities and predictions of 2025on April 8, 2020 at 10:08 pm
The MarketWatch News Department was not involved in the creation of the content. Apr 09, 2020 (Profound via COMTEX) -- Polio Vaccines Market 2019 Report offers a professional and in-depth study on the ...
- More Coronavirus Vaccines and Treatments Move Toward Human Trialson April 8, 2020 at 4:27 pm
Just three months after the start of the coronavirus pandemic, several biotech companies are beginning trials of promising vaccines and treatments.
- Coronavirus vaccines are moving to clinical trials. So why are they still so far away?on April 8, 2020 at 11:51 am
The process of developing a vaccine is complex because it involves extensive clinical trials to determine if it’s safe. Scientists can use other vaccines as roadmaps for developing one for COVID-19, ...
- Anthrax Vaccines Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2024on April 8, 2020 at 9:29 am
Apr 08, 2020 (The Expresswire) -- Request now -"Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Anthrax Vaccines Market“ Report 2020report recorddetailed ...
- Coronavirus treatments: Hydroxychloroquine, vaccines and drugs for COVID-19on April 7, 2020 at 8:41 pm
Vaccine candidates to treat COVID-19 are already being trialed in animals and humans, but there's one anti-malarial that keeps making headlines.
- Pandemic expert calls for manufacturing coronavirus vaccines before they're proven to workon April 7, 2020 at 12:05 pm
Still, Hatchett believes it's important to begin production of some potential vaccines before they're proven to work. Hatchett said if the hope is to get vaccines out as quickly as possible while also ...
via Bing News